Alcon, the eye-care business that Novartis AG acquired for more than $50 billion, is now weighing on Europe’s second-largest drugmaker. After more than a year of efforts to turn around the business, the Swiss company on Wednesday said it was considering all options for the embattled division, including a spinoff or initial public offering.
Category: Novartis
Novartis Misses Q4 Earnings Estimate, Mulls Alcon Spin-Off
Novartis missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit. Novartis AG missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit.